Aligos Therapeutics, Inc. (ALGS) Insider Trading & SEC Filings
Updated Jul 16, 2026 · Last SEC filing 2026-06-29
Aligos Therapeutics, Inc. (ALGS) has filed 6 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-06-29. 3 Form 8-K material event filings were reported by ALGS in the last 90 days. InsiderAlpha tracks every ALGS SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.
— Item 1.01 · Contract · positive [SEC] Aligos Therapeutics entered into an exclusive license agreement with Xiamen Amoytop Biotech to develop and commercialize pevifoscorvir sodium for Hepatitis B and Hepatitis B/D co-infection treatment in mainland China, Taiwan, Hong Kong, and Macau. This partnership expands the com
— Item 8.01, 9.01 · Clinical · positive [SEC] Aligos Therapeutics announced positive interim analysis results from the Phase 2 B-SUPREME study of pevifoscorvir sodium for chronic hepatitis B, with the independent Data Safety Monitoring Board recommending continuation and increased sample size for the HBeAg- cohort. The FDA a
— Item 2.02, 9.01 · Earnings · neutral [SEC] Aligos Therapeutics issued a press release on March 5, 2026 reporting results of operations and financial condition. The filing provides standard financial results disclosure without specific performance metrics or guidance changes detailed in the excerpt.
SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in ALGS insider filings:
P
Open-market purchase by the insider
S
Open-market sale by the insider
A
Grant, award, or other acquisition from the issuer
M
Exercise or conversion of derivative security (e.g. options)
F
Payment of exercise price or tax liability via share withholding
G
Bona-fide gift of securities
D
Disposition to the issuer (e.g. share buyback participation)
J
Other acquisition or disposition
X
Exercise of in-the-money or at-the-money derivative security
C
Conversion of derivative security
V
Transaction voluntarily reported earlier than required
ALGS Insider Trading — FAQ
What is the latest insider trade for ALGS?
Aligos Therapeutics, Inc. (ALGS) had 6 insider filings in the last 90 days, with the most recent on 2026-06-29. InsiderAlpha tracks every Form 4, 10-K, 10-Q, and 8-K filing in real time.
How many insiders are buying ALGS stock?
0 insider purchases of ALGS were filed in the last 90 days.
How many insiders are selling ALGS stock?
0 insider sales of ALGS were filed in the last 90 days.
Where can I see ALGS SEC filings (Form 4, 10-K, 10-Q, 8-K)?
InsiderAlpha aggregates every ALGS SEC filing — Form 4 insider transactions, 10-K and 10-Q quarterly reports, and 8-K material event disclosures — in one timeline.